Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - calcitonin, salmon - solution for injection - calcitonin, salmon 100 iu - calcium homeostasis

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - calcitonin - solution for injection/infusion - calcitonin 100 iu - calcium homeostasis

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - calcitonin - solution for injection/infusion - calcitonin 100 iu/ml - calcium homeostasis

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - calcitonin salmon, quantity: 100 iu/ml - injection, solution - excipient ingredients: sodium acetate; sodium chloride; glacial acetic acid; water for injections - - active paget's diseasein patients who do not respond to alternative treatments or for whom such treatments are not suitable,- hypercalcaemia.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 2200 [iu] in 1 ml - fortical® calcitonin-salmon (rdna origin) nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. use of fortical® calcitonin-salmon (rdna origin) nasal spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin d (400 international units per day) intake to retard the progressive loss of bone mass. the evidence of efficacy for calcitonin-salmon is based on increases in spinal bone mineral density (bmd) observed in clinical trials. two randomized, placebo-controlled trials were conducted in 325 postmenopausal women (227 treated with calcitonin-salmon nasal spray and 98 treated with placebo) with spinal, forearm or femoral bmd at least one standard deviation below the normal value for healthy premenopausal women. these studies conducted over two years demonstrated that 200 international units daily of calcitonin-salmon nasal spray

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 2200 [iu] in 1 ml - fortical nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. fortical nasal spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4) ]. - calcitonin-salmon nasal spray has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin-salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1) ]. pregnancy category c: risk summary there are no adequate and well-controlled

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon nasal solution is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. calcitonin salmon nasal solution should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4)]. - calcitonin salmon nasal solution has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin-salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1)]. risk summary calcitonin salmon nasal solution is not i

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - salcatonin/calcitonin salmon -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - salcatonin/calcitonin salmon -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - calcitonin salmon -